The company has developed an NGS-based discovery approach that allows it to more thoroughly explore the antibody repertoire produced by immunized animals.
Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.
The researchers are currently incorporating new technology that they say will shave an additional two to three weeks off their antibody generation workflow.
It will purchase AxioMx for $20 million followed by additional performance-based payments totaling up to $25 million to be paid over the next five years.
The deal gives Abcam exclusive access to more than 1,800 human diploid and haploid cell lines from Horizon's X-MAN collection.
Abcam was encouraged to buy Firefly BioWorks by its customers, who are more frequently complementing their protein analysis work with miRNA studies.
The all-cash deal gives Abcam access to Firefly's multiplex assay biomarker-detection platform.
Abcam, a Cambridge, UK-based provider of antibody microarrays, this week announced a series of management changes.
AB Sciex this week launched its new Academic Partnership Program, an initiative designed to support academic researchers in the 'omics fields.
Abcam paid $4.2 million in cash and issued $1.8 million in company stock for MitoSciences, which develops mitochondrial antibodies and assays.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.
Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.
In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.